Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Cytomegalovirus Infection and Vaccine Development"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2019) | Viewed by 28199
Special Issue Editor
Interests: cytomegalovirus; vaccines; immune response; T cells; neutralizing antibodies; viral vectors; peptides; antigen receptors
Special Issue Information
The Type 5 herpes virus cytomegalovirus (CMV) has been extensively studied since its discovery in 1956. The immunology of infection has been of high interest, since it was discovered that transplant recipients, either stem cell or solid organ, develop T cell responses to viral antigens. The first successful adoptive immunotherapy was applied to stem cell transplant recipients as a therapy to protect against CMV viremia. Throughout the last four decades, various subunit and whole virus vaccine strategies have been developed and tested in transplant recipients with mixed results. Simultaneously, vaccine strategies to protect the developing fetus from maternal CMV infection have been pursued. The best results, and they are imperfect, have been with protein-based gB vaccine formulations. In this monograph, we will consider a selection of CMV vaccine strategies as solutions to the dual problem of prophylaxis of women of child-bearing years and the therapy of the immunosuppressed transplant recipient. While CMV viruses are exquisitely species-specific, homologous viruses and animal models have contributed to a better understanding of the correlates of protective immunity. While there is no licensed CMV vaccine for any population, there is considerable will to overcome the obstacles that hinder the successful development of either a prophylactic or a therapeutic vaccine.
Prof. Dr. Don J. Diamond
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Immune response
- T cells
- Neutralizing antibodies
- Viral vectors
- RNA vaccines
- Congenital infection